Department of Radiation Biology

Hans Skovgaard Poulsen, MD, DMSc

Department of Radiation Biology,
The Finsencenter, Section 6321
Copenhagen University Hospital,
Blegdamsvej 9
DK - 2100 Copenhagen
Email: hans.skovgaard.poulsen@regionh.dk
Phone: (+45) 35 45 63 03 Fax: (+45) 35 45 63 01
Date of Birth: June 23rd. 1949
Current Position:
Associate Research professor, Chief Physician and Head of Section for Neuro-Oncology and Department of Radiation Biology
1988Specialist in Oncology and Radiotherapy
1984Doctoral Thesis (DMSc.), University of Aarhus, Denmark
1981-82Senior Research Fellow in Pathology and Oncology, Columbia Presbyterian Hospital,
College of Physician and Surgeons, New York, USA
1978MD, University of Aarhus, Denmark
Clinical Responsibilities:
Neuro-oncology (Head)
Research responsibilities:
Initiated and was head of the Receptor Laboratory, The Danish Cancer Society, Aarhus from
1980 to 1989. This laboratory developed new histological methods for oestrogen receptor
assays and was one of 3-reference laboratory in Denmark.
Initiated and is head of Department of Radiation Biology, Finsen Centre since 1993.
Present research area: Lung cancer, brain tumors and growth factor receptor studies, with
the principal aim to generate more insight into the malignant phenotype, and second aim to
extend that knowledge to patient material in terms of testing possible prognostic factors, as
well as suggesting new translational treatment modalities; targeting gene therapy alone or in
combination with already used modalities.
The laboratory employs 10 people, 1 senior research scientists, 1 resarch assistant, 1 associated research assistant, 4 Ph.D. students, 2 technicians, 1 research nurse.
The laboratories have mainly been financed by competitive money from The Danish Medical Research Council, The Danish Cancer Society, University of Copenhagen, Rigshospitalet and several private foundations.
Supervision experiences: Mentor (2) and co-mentor (1) for doctoral theses;
24 Ph.D. Studies, 21 Approved, the rest in progress.
In addition several student projects have been supervised.
Evaluation of 19 PhD thesis and 11 Doctor thesis at the University Of Copenhagen, Aarhus, Odense, Lund, Bergen and the University of Dublin.
Referee for a number of international scientific journals.
Member of several scientific and clinical evaluation boards often as chairman.

Other functions:
1990-1994President, the Danish Association for Cancer Research
1992-1996Initiated Dansk Kræftforsknings Fond and member of the Board of Directors
1993-Member of EORTC’s Brain tumor Group
1995-1997Member of the Scientific Committee of Ethics for Copenhagen and Frederiksberg
1994-2000Member of the Editorial Board of Lung Cancer
1996-2002:Member of the scientific Board, The Danish Cancer Society
1996-2000Member of the Board, the European Association of Neuro-Oncology
1997-2006Secretary, the Danish Brain Tumor Study Group (DBTSG)
1998-2006Member of the Editorial Board of Neuro-Oncology
1999-2007Board member, Patent administration, Biotechnology, University Hospital,
1999-2002CSO, Odin Medical A/S
2000President, EANO 2000
2000-2007President, Scandinavian Neuro-Oncology Group (SNOG)
2003-Member of the National Board of Patients´ Complaints of the Danish Public Health
2006-Board member of Danish Graduate School in Clinical Oncology
2007-Member of the scientific Board, The Norwegian Cancer Society
2009-Visiting Professor at The Preston Robert Tisch Brain Tumor Center at Duke
2009-EU Evaluation Commission, FP7-Health 2010
2010-Member of the Scientific Advisory Board, University of Catanzaro Magna Græcia,
Catanzaro, Italy
2010-Member of the executive board, Danish Neurooncology group -DNOG
2012-EU FP7: Glioma Actively Personalized Vaccine Consortium; granted by EU
2012-Coordinator of Neurooncology, Copenhagen Comprehensive Cancer Center - 4C
2012-Member of professor evaluation board, Duke University, NC, USA.
2014- 2016
President, Scandinavian Association for Neuro-Oncology (SNOG)
2014-Scientific advisor, French National Cancer Institute - Institut National du Cancer –INCa, France.

Member of the following scientific associations:
The Danish Association for Cancer Research since 1980
The European Association for Cancer Research - EACR since its beginning
The American Association for Cancer Research - AACR since 1982
Society for Neurooncology - SNO since 1993
The European Association of Neuro-Oncology - EANO since 1993
The Danish Society for Oncology since 1988
International association for the study of Lung cancer - IASLC since 1988
American Society for Gene and Cell Therapy - ASGCT since 2000
European Organization for Research and Treatment of Cancer - EORTC since 1993
Organized the Clinical Oncology service at Faroe Islands and Greenland.
Teaching experience:
Associate professor, University of Copenhagen; human biology and oncology since 1993
Since 1976 participated in more than 200 scientific meetings, national as well as international and has presented more than 200 scientific papers, either nationally or internationally, often as invited speaker.

1976Gold medal for Prize paper in Oncology, University of Aarhus
1986ESTRO travelling award
1998Kaj Bunch-Jensen and Allis Bunch-Jensen’s award for Cancer Research
2008The honouree award of the Danish Society for Cancer Research
     1Prize paper in Oncology, awarded Gold medal from Aarhus University 1976:Der ønskes en undersøgelse af en in vitro metode til påvisning af humane mammacancercellers hormonfølsomhed. Undersøgelsen skal baseres på litteraturstudier og egen metodik. 
     1 Doctoral thesis:In vitro tests and hormonal treatment of breast cancer.  
 199Original articles in scientific journals with peer-review
     5Submitted papers to scientific journals with peer-review
    10Original articles in journals without peer-review
     9Book chapters
     3 Patents
Articles with peer review:
1.Poulsen HS: Demonstration of hormonal sensitivity in gynaecomastic tissue by thymidine incorporation in vitro.
Acta path microbiol scand (section A), 85: 19-24, 1977.
2.Overgaard J, Poulsen HS: Brief Communication: Effect of hyperthermia and environmental acidity on the proteolytic activity in murine ascites tumor cells.
J Natl Cancer Inst, 58: 1159-1161, 1977.
3.Poulsen HS: Absence of association between oestrogen-receptor content and in vitro oestrogen sensitivity in human breast cancer.
Acta path microbiol scand (section A), 86: 169-172, 1978
4.Nielsen HE, Poulsen HS, Olsen KJ, Gadeberg CC, Schultz H: Bone mineral
content and estrogen receptors in patients with breast cancer.
Europ. J. Cancer, 15: 703-707, 1979.
5.Poulsen HS, Schultz H, Bichel P: Oestrogen-receptor determinations on fine-needle aspirations from malignant tumours of the breast.
Europ J. Cancer, 15: 1431-1438, 1979.
6.Mørch-Jørgensen L, Poulsen HS, Larsson L-I: Formaldehyde-Fluorescamine- induced fluorescence of mammary carcinoma cells. Lack of concordance with occurence of Oestrogen-binding proteins.
Virchows Arch B Cell Path, 30; 281-287, 1979
7.Poulsen HS, Schultz HP, Hansen ES: Østrogen receptorbestemmelse på malignt humant mammavæv. Hvorledes undgås falsk negative resultater?
Ugeskr. Læg, 143: 192-194, 1981.
8.Poulsen HS: Oestrogen Receptor Assay-Limitation of the Method.
Europ. J. Cancer 17: 495-501, 1981
9.Poulsen HS, Jensen J, Hermansen C: Human breast cancer: Heterogeneity of estrogen binding sites.
Cancer, 48: 1791-1793, 1981.
10.Poulsen HS, Frederiksen P: Glucose-6-phosphate dehydrogenase activity in human breast cancer. Lack of association with estrogen receptor content.
Acta path. microbiol scand. (section A), 89: 263-270, 1981.
11.Poulsen HS, Bichel P, Andersen J: Short-term culture of human breast cancer: In vitro effects of hormones related to patient response.
Br J Cancer, 46: 67-74, 1982.
12.Bichel P, Poulsen HS, Andersen J: Estrogen receptor content and ploidy of human mammary carcinoma.
Cancer, 50: 1771 - 1774, 1982
13.Poulsen HS, L. Ozzello L, Andersen J: Oestrogen receptors in human breast cancer. Problems of correlation with histopathological features.
Virchows Arch ( Pathol Anat ), 397: 103-108, 1982.
14. Poulsen HS: Estrogen receptors in human breast cancer. Comparative features of the hydroxylapatite- and Dextran-coated charcoal assay.
Eur J Cancer Clin Oncol, 18: 1075-1079, 1982.
15.Poulsen HS: In vitro tests and hormonal treatment of breast cancer.
Progress in Surgical Pathology, pp 37-65., 1983.
16.Hermansen C, Poulsen HS, Jensen J, Langfeldt JB, Steenskov V, Frederiksen P, Jensen OM: Palpable breast tumours: "Triple diagnosis" and operative strategy, Results of a prospective study.
Acta Chir Scand, 150: 625-628, 1984
17.Poulsen HS, Bukh A, Rytter L, Thomsen K, Ørntoft T, Andersen HU, Møller NPH, Brünner N: Oestrogen receptor assay. False positive analysis?
Acta Radiologica Oncology, 23: 109-117, 1984.
18.Jacobsen A, Poulsen HS, Madsen EL, Petersen SE, Hansen HS: Ploidy level of human breast carcinoma. Relation to histopathologic features and hormone receptor content.
Acta Radiologica Oncology, 23: 103-107, 1984.
19.Thorpe SM, Olsen K, Pedersen KO, Poulsen HS, Rose C: Quality control of estrogen and progesterone receptor analyses in Denmark.
Res Results Cancer Res, 91: 91-93, 1984.
20. Poulsen HS, Ozzello L, King WJ, Greene GL: The use of monoclonal antibodies to estrogen receptors (ER) for immunoperoxidase detection of ER in paraffin sections of human breast cancer tissue.
J Histochem Cyto¬chem, 33: 87-92, 1985.
21.Ørntoft TF, Mors NPO, Eriksen G, Jacobsen NO, Poulsen HS: Comparative immunoperoxidase demonstration of T-antigens in human colorectal carcinomas and morphologically abnormal mucosa.
Cancer Res, 45: 447-452, 1985.
22.Brünner N, Spang-Thomsen M, Poulsen HS , Engelholm SA, Nielsen A, Vindeløv L: Endocrine sensitivity of the receptor-positive T61 human breast carcinoma serially grown in nude mice.
Int J Cancer, 35: 59-64, 1985.
23.Brünner N, Bastert GB, Poulsen HS, Spang-Thomsen M, Engelholm SA, Vindeløv L, Nielsen A, Tommerup N, Elling F: Characterization of the T61 human breast carcinoma established in nude mice.
Eur J Cancer Clin Oncol, 21: 833-843, 1985.
24.Nielsen HE, Saksø P, Poulsen HS, Gadeberg CC: Bone mineral content and estrogen receptors in women with breast tumors.
Acta Radiologica Oncology, 24: 247-251, 1985.
25.Poulsen HS, Hermansen C, Andersen JA, Andersen HU, Jensen J: Gynecomasty: Estrogen and androgen receptors. A clinical-pathological inves¬tigation.
Acta path. microbiol. immunol. scand. (section A), 93: 229-233, 1985.
26.Nielsen NSM, Poulsen HS: Relation between mammagraphic findings and hormonal receptor content in breast cancer.
Am J Roentgenology, 145: 501-504, 1985.
27.Andersen J, Ørntoft TF, Poulsen HS: Semiquantitative oestrogen receptor assay in formalin-fixed paraffin sections of human breast cancer tissue using monoclonal
antibodies. Br J Cancer, 53: 691-694, 1986
28.Rose C, Kamby C, Mouridsen HT, Bastholt L, Brincker H, Poulsen HS, Andersen AP, Loft H, Dombernowsky P, Andersen KW: Com¬bined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone.
Breast Cancer Res Treat, 7: 45-50, 1986.
29.Hermansen C, Poulsen HS , Jensen J, Langfeldt B, Steenskov V, Frederiksen P, Jensen OM: Diagnostic Reliability of Combined Physical Examination, Mammography and Fine-Needle Puncture ("Triple Test") in Breast Tumors. A Prospective Study.
Cancer, 60: 1866-1871, 1987.
30.Andersen J, Andersen JA, Ørntoft TF, Poulsen HS: Gynecomastia: Immunohistochemical demonstration of estrogen receptors.
Acta path. microbiol. immunol. scand.( Section A ), 95: 263-267, 1987.
31.Andersen J, Poulsen HS: Immunohistochemical analysis of estrogen receptors (ER) using formalin-fixed paraffin-embedded breast cancer tissue: Correlation with clinical endocrine response.
J. steroid Biochem, 30: 337-339, 1988.
32.Bentzen SM , Poulsen HS, Kaae S, Jensen OM, Johansen H, Mouridsen HT, Daugaard S, Arnoldi C: Prognostic factors in osteosarcomas. A regression analysis.
Cancer, 62: 194-202, 1988.
33.Jacobsen A, Hansen V, Poulsen HS: DNA profile and steroid receptor content of human ovarian cancer.
Eur J Gynaec Oncol, 6: 461-463, 1988.
34.Andersen J, Bentzen SM, Poulsen HS: Relationship between radioligand binding assay, immunoenzyme assay and immunohistochemical assay for estrogen receptors in human breast cancer and association with tumor differentiation.
Eur J Cancer Clin Oncol, 24: 377-384, 1988.
35.Bukh A, Agua MT, Krarup N, Poulsen HS, Nordentoft AM, Møller NP: A prospective study of circulating immune complexes in patients with breast cancer.
Int. J Cancer, marts 15; 41,364-70, 1988.
36.Thorpe SM, Poulsen HS, Pedersen KO, Rose C: Impact of standardization of estrogen and progesterone receptor assays of breast cancer biopsies in Denmark.
Eur J Cancer Clin Oncol, 24: 1263-1269, 1988.
37.Andersen J, Ørntoft TF, Poulsen HS: Immunohistochemical demonstration of estrogen receptors (ER) in formalin-fixed, paraffin-embedded human breast cancer tissue by use of a monoclonal antibody to ER1.
J histochem Cytochem, 36: 1553-1560, 1988.
38.Andersen J, Poulsen HS: Relationship between estrogen receptor status in the primary tumor and its regional and distant metastases. An immunohistochemical study in human breast cancer.
Acta Oncologica, 27: 761-765, 1988
39.Thorpe SM, Poulsen HS, Pedersen KO, Rose C: Quality control of receptor analyses of breast cancer tissue in Denmark.
Acta Oncologica, 27: 621 - 625, 1988.
40.Andersen J, Skovbon H, Poulsen HS: Immunocytochemical determination of the estrogen regulated protein Mr 24.000 in primary breast cancer and response to endocrine therapy.
Eur J Cancer Clin Oncol, 25: 641-643, 1989
41.Scopsi L, Balslev E, Brünner N, Poulsen HS, Andersen J, Rank F, Larsson L-I: Immunoreactive opioid peptides in human breast cancer.
American J Pathol, 134, 2: 473-479, 1989.
42.Andersen J, Poulsen HS: Immunohistochemical Estrogen Receptor Determination in Paraffin Embedded Tissue. Prediction of response to hormonal treatment in advanced breast cancer.
Cancer, 64: 1901 - 1908, 1989
43.Jørgensen LJ, Poulsen HS, Nordentoft AM, Jensen OM, Sneppen O: Sarcoma Synoviale.
Ugeskr Læger, 151: 1325-1328, 1989.
44.Nielsen OS, Poulsen HS: Knoglemetastaser.
Ugeskr Læger, 151: 362-365, 1989.
45.Poulsen HS, Nielsen OS, Klee M, Rørth M: Palliative irradiation of Bone Metastases.
Cancer Treat Review, 16: 41-48, 1989
46.Rørth M, Poulsen HS: Behandling af Kræftsygdomme.
Ugeskr Læger, 151: 325-330, 1989.
47.Damstrup L, Rørth M, Poulsen HS: Growth factors and growth factor receptors in human malignancies, with special reference to human lung cancer: a review.
Lung Cancer, 5: 49-68, 1989
48.Poulsen HS: Cancer cell cultures and their clinical application.
Reviews Endocrine-Related Cancer, 33: 17-22, 1989.
49.Krarup-Hansen A, Poulsen HS: Extra-visceral soft tissue sarcomas in adults: local treatment, with special reference to irradiation.
Cancer Treat Reviews, 16: 221-246, 1989
50.Andersen J, Thorpe SM, King WJ, Rose C, Christensen I, Rasmussen BB, Thorpe SM, Poulsen HS: The prognostic value of immunohistochemical estrogen receptor analysis inparaffin-embedded and frozen sections versus that of Steroid-binding assays.
Eur J Cancer Clin Oncol, 26: 442-449, 1990.
51.Mouridsen HT, Dombernowsky P, Jensen OM, Johansen H, Lund B, Nordentoft A,, Poulsen HS,Schiødt T, Sneppen O: Sarkom Behandling i Danmark.
Ugeskr Læger, 152: 989-992, 1990
52.Andersen J, Thorpe SM, Rose C, Christensen I, Rasmussen BB, Poulsen HS : Estrogen receptor in primary breast cancer estimated in paraffin-embedded tissue. A study of its usefulness compared to dextran-coated charcoal assay.
Acta Oncologica, 30: 685-690, 1991
53.Becker U, Andersen J, Poulsen HS, Burcharth F, Gluud C, Horn T: Enzyme immunoassay of oestrogen receptors in needle biopsies from human liver.
Liver, 11: 292-299, 1991.
54.Hippe E, Jønsson V, von der Maase H, Mathiesen JC, Poulsen HS: Homoeostatic response criteria for cancer therapy.
Eur J Cancer, 27: 1715-1716, 1991.
55.Nørgaard P, Poulsen HS: Glucocorticoid receptors in human malignancies: A review.
Ann Oncol, 2: 541-557, 1991
56.Nielsen NSM, Andersen J, Poulsen HS, Mathiessen O: Prediction of hormone responsiveness by mammographic parenchymal pattern in advanced primary breast cancer.
Breast Cancer Res Treat, 23: 219-222, 1992
57.Damstrup L, Andersen J, Kufe DW, Hayes DF, Poulsen HS: Immunocyt-ochemical determination of the Estrogen-regulated proteins Mr 24.000,Mr 52.000 and DF3 breast cancer associated antigen:Clinical value in advanced breast cancer and correlation with estrogen receptor.
Ann Oncol, 3: 71-77, 1992
58.Becker U, Andersen J, Poulsen HS, Horn T: Variation in hepatic estrogen receptor concentrations in patients with liver disease: A multivariate analysis.
Scand J Gastroenterol, 27: 355-361, 1992
59.Damstrup L, Rygaard K, Spang-Thomsen M, Poulsen HS: Expression of the Epidermal Growth Factor Receptor in Human Small Cell Lung Cancer Cell Lines.
Cancer Res 52: 3089- 3093, 1992.
60.Nørgaard P, Damstrup L, Spang-Thomsen M, Poulsen HS: Trans¬forming growth factor- b. En potent multifunktionel vækstfaktor for normale og maligne celler.
Ugeskr Læger, 154: 3494-3498, 1992.
61.Becker U, Andersen J, Poulsen HS,Horn T: Hepatic cytosolic oestrogen receptors in patients with liver disease.
J Intern Med. Feb; 233(2), 165-72, 1993
62.Damstrup L, Rygaard K, Spang-Thomsen M, Poulsen HS: Expression of transforming growth factor b (TGF b) receptors of TGF b 1, TGF b 2, and TGFb 3 in human small cell lung cancer cell lines.
Br J Cancer, 67: 1015-1021, 1993.
63.Nørgaard P, Damstrup L, Rygaard K, Spang-Thomsen M, Poulsen HS: Growthsuppresion by transforming growth factor b of human small cell lung cancer cell lines is associated with expression of type II receptor.
Br J Cancer, 69: 802 - 808, 1994
64.Damstrup L, Poulsen HS: Review of the curative role of radiotherapy in the treatment of non - small cell lung cancer.
Lung Cancer, 11: 153- 178, 1994
65.Bouchelouche PN, Berild D, Nielsen OH, Elmgreen J, Poulsen HS : Leukotriene B4 receptor levels and intracellular calcium, signalling in polymorpho- nuclear leukocytes from patients with Chron’s disease.
Eur J Gatroent Hepatol, 7: 349 - 356, 1995.
66.Nørgaard P, Hougaard S, Spang-Thomsen M, Poulsen HS: Transforming Growth Factor b and Cancer.
Cancer Treat Reviews, 21: 367 - 403, 1995
67.Poulsen HS, Sørensen JB: Management of patients with Lung Cancer.
Oncology in Practice, 1995
68.Nørgaard P, Spang-Thomsen M, Poulsen HS: Expression and autoregulation of transforming growth factor b receptor mRNA in small- cell lung cancer cell lines.
Br J Cancer, 73: 1037 - 1043, 1996.
69.Nørgaard P, Damstrup L, Rygaard K, Spang-Thomsen M, Poulsen HS: Acquired TGF -b1 sensitivity and TGF-b1 expression in cell lines established from a single small cell lung cancer patient during clinical progression.
Lung Cancer, 14: 63 - 73, 1996
70.Kristensen CA, Jensen PB, Poulsen HS, Hansen HH: Small Cell Lung Cancer: Biological and therapeutic aspects.
Critical Review in Oncology/ Hæmatol, 22: 27 - 60, 1996
71.Pedersen AN, Højer-Hansen G, Brünner N, Clark GM, Larsen B, Poulsen HS, Danø K, Stephens RW: The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA.
J Immun Methods, 203: 55 - 65, 1997
72.Krarup M, Poulsen HS, Spang-Thomsen M: Cellular Radiosensitivity of small-cell lung cancer cell lines.
Int J Radiation Oncology Biol Phys, 38: 191 - 196, 1997
73.Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS: Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials.
Ann Oncol, 8: 1197 - 1206, 1997
74.Helin K, Holm K, Niebuhr A, Eiberg H, Tommerup N, Hougaard S, Poulsen HS, Spang-Thomsen M, Nørgaard P: Loss of the retinoblastoma protein - related p130 protein in small cell lung carcinoma.
Proc Natl Acad Sci, 94: 6933 - 6938, 1997
75.Damstrup L, Voldborg BR, Spang-Thomsen M, Brunner N, H. Poulsen HS: In vitro invasion of small - cell lung cancer cell lines correlates with expression of epidermal growth factor receptor.
Br J Cancer, 78: 631 - 640, 1998.
76.Hougaard S, Krarup M, Nørgaard P, Damstrup L, Spang-Thomsen M, Poulsen HS: High value of the radiobiological parameter Dq correlates to expression of the transforming growth factor b type II receptor in a panel of small cell lung cancer cell lines.
Lung Cancer, 20, 65 - 69, 1998
77.Lassen U, Andersen P, Daugaard G, Holm S, Jensen M, Svarre C, Poulsen HS, Paulson OB: Metabolic and hemodynamic evaluation of brain metastases from small cell lung cancer with positron emission topography.
Clin. Cancer Res., 501-3, 1998
78.Lund EL, Spang-Thomsen M, Poulsen HS, Kristjansen PEG: Tumor angiogenesis - a new therapeutic target in gliomas.
Acta Neu Scand, 97: 52 - 62, 1998
79.Damstrup L, Kuwada SK, Dempsey PJ, Brown CL, Hawkey CJ, Poulsen HS, Wiley HS, Coffey RJ: Amphiregulin acts as an autocrine growth factor in two human polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis.
Br J Cancer, 80: 1012 - 1019, 1999.
80.Nørgaard P, Law B, Joseph H, Page DL, Shyr Y, Mays D, Pietenpol JA, Kohl NE, Oliff A, Coffey RJ, Poulsen HS, Moses HL: Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) apha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis.
Clin Cancer Res, 5: 35 - 42, 1999
81.Hougaard S, Nørgaard P, Abrahamsen N, Moses HL, Spang-Thomsen M, Poulsen HS:  Inactivation of the transforming growth factor b type II receptor in human small cell lungcancer cell lines.
Br J Cancer, 79: 1005 - 1011, 1999
82.Lassen U, Kristjansen PEG, Wagner Aa, Kosteljanetz M, Poulsen HS: Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study.
J NeuroOncol, 43: 161 - 166, 1999
83.Schmiegelow M, Weber L, Lassen S, Poulsen HS , Hertz H, Müller J: Dosimetry and growth hormone deficiency following cranial irradiation of childhood brain tumors.
Med Pediatr Oncol, 33: 564 - 571, 1999.
84.Law BK, Nørgaard P, Gnudi L, Kahn BB, Poulsen HS, Moses HL: Inhibition of DNA Synthesis by a Farnesyltransferase Inhibitor Involves Inhibition of the p70 (s6k) Pathway
J Biol Chem, 19: 4743 - 4748, 1999
85.Nørgaard P, Law BK, Poulsen HS, Moses HL: Farnesyltransferase inhibitor-induced regression of mammary tumors in TGF alpha and TGF alpha/neu transgenic mice correlates with inhibition of map kinase and p70s6 kinase phosphorylation.
Ann N Y Acad Sci, 886: 265-8, 1999
86.Frederiksen KS, Petri A, Abrahamsen N, Damstrup L, Poulsen HS: Gene therapy for Lung Cancer.
Lung Cancer, 23: 191- 107, 1999
87.Frederiksen KS, Abrahamsen N, Cristiano RJ, Damstrup L, Poulsen HS: Gene delivery by an epidermal growth factor/ DNA polyplex to small cell lung cancer cell lines expressing low levels of epidermal growth factor receptor.
Cancer Gene Ther, 7: 262 - 268, 2000.
88.Schmiegelow M, Lassen S, Poulsen HS, Feldt-Rasmussen U, Schmiegelow K., Hertz H, Müller JR: Biological Effective Dose-GH-Deficiency. Cranial radiotherapy of childhood brain tumors: Growth hormone deficiency and the relation to the biological effective dose of irradiation in a large population based study.Clin Endocrinol (Oxf);53(2): 191-7, 2000
89.Schmiegelow M, Lassen S, Poulsen HS, Feldt-Rasmussen U, Schmiegelow K, Hertz H, Müller JR:Growth Hormone Response to a Growth Hormone Releasing Hormone Stimulation Test in a Population Based Study Following Irradiation of Childhood Brain Tumours.
Horm Res, 54(2): 53-59, 2000
90.Pedersen MW, Thykjær T, Ørntoft TF, Damstrup L, Poulsen HS: Profile of differentially expressed genes mediated by the Type III Epidermal Growth Factor Receptor mutation in small cell lung cancer cell line.
Br J Cancer; 85( 8 ): 1211 - 1218, 2001
91.Schmiegelow M, Lassen S, Poulsen HS, Schmiegelow K, Hertz H, Andersson AM, Skakkebæk NE, Müller J: Gonodal status in male survivors following childhood brain tumors.
J Clin Endocrin Metab, 86: 2446 - 2452, 2001
92.Wurtzen PA, Pedersen L, Poulsen HS, Claesson MH: Specific killing of P53 mutated tumor cell lines by cross-reactive huam HLA-A2-restricted P53-specific CTL line.
Int J Cancer, 93: 855-861, 2001
93.Pedersen MW, Meltorn M, Poulsen HS: The Type III EGF receptor growth factor mutation.
Ann Oncol, 12: 745 – 760, 2001.
94.Damstrup L, Pedersen MW, Bastholm L, Elling F, Poulsen HS: Epidermal Growth Factor Receptor Mutation Type III transfected into small cell lung cancer cell line is predominantly localized at the cell surface and enhance tumorigeneity.
Int J Cancer, 97: 7 -14, 2002.
95.Mortensen S, Sørensen SB, Poulsen HS: Genterapi og cancer.
Ugskrf Læger, 164: 1785 - 1790, 2002.
96.Pedersen MW, Poulsen HS: Epidermal Growth Factor Receptor in Cancer Therapy.
Science & Medicine, august: 206- 217, 2002
97.Schmiegelow M, Feldt-Rasmussen U, Rasmussen ÅK, Hertz H, Poulsen HS, Müller J: Thyroid function in Childhood brain tumor. A population based study of Thyroid function after Radiotherapy and Chemotherapy for a Childhood brain tumor.
J Clin Endocrinol Metab, 88(1): 136-40, 2003.
98.Hansen LRT, Lundin C, Helleday T, Poulsen HS, Petersen LN, Spang-Thomsen M: DNA repair rate and etoposide resistance in two tumor cell subpopulations derived from a single human small cell lung cancer.
Lung Cancer, 40(2): 157-64, 2003
99.Pedersen N, Mortensen S, Sørensen SB, Pedersen MW, Rieneck K, Bovin LF, Poulsen HS: Transcriptional gene expression profiling of small cell lung cancer cells.
Cancer Res 63(8):1943-53. 2003
100.Nielsen KL, Allen MR, Bloomfield SA, Andersen TL, Chen X, Xu T, Poulsen HS, Young MF, Heegaard M: Biglycan Deficiency interferes with overiectomy-induced bone loss.
J Bone Miner Res, 18(12): 2152-2158, 2003
101.Schmiegelow M, Feldt-Rasmussen U, Rasmussen AK, Lange M, Poulsen HS, Müller J: Assessment of the Hypothalamo-Pituitary-Adrenal Axis in Patients treated with Cranial Radiotherapy for a Childhood Brain Tumor.
J Clin Endocrinol Metab, 88(7): 3149-54, 2003.
102.Heydenreich AV, Westmeier R, Pedersen N, Poulsen HS, Kristensen HG: Preparation and purification of cationic nanospheres - effects on particle size, physical stability and cell toxicity.
Int J Pharm, 254: 83-87, 2003.
103.Pedersen N, Poulsen HS: New drug modalities for treatment of lung cancer.
Review Series Oncology, 2/2003: 2-6, 2003.
104.Pedersen MW, Tkach V, Pedersen N, Berezin V and Poulsen HS: Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases cell motility.
Int J Cancer, 108: 643-653, 2004.
105.Christensen HC, Schüz J, Kosteljanetz M, Poulsen HS, Thomsen J, Johansen C: Cellular telephone use and risk for acoustic neurinoma.
Am J Epidemiology, 159(3): 277-83, 2004
106.Pedersen MW, Pedersen N, Damstrup L, Villingshøj M, Sønder SU, Rieneck K, Bovin LF, Spang-Thomsen M, Poulsen HS: Analysis of the epidermal growth factor receptor specific transcriptome: effect of expression level and an activating mutation.
J Cell Biocem, 96(2): 412-427, 2005
107.Poulsen TT, Pedersen N, Perin MS, Celia K, Hansen CK, Poulsen HS: Specific sensitivity of small cell lung cancer cell lines to the snake venom toxin taipoxin.
Lung Cancer, 50(3): 329-337, 2005
108.Christensen HC, Schüz J, Kosteljanetz M, Poulsen HS, Boice J, McLaughlin, Johansen C: Cellular telephone and risk for brain tumors. A population-based, incident case-control study.
Neurology, 64(7): 1189-95, 2005
109.Pedersen MW, Pedersen N, Ottesen LH, Poulsen HS: Differential response to gefinitib of cells expressing normal EGFR and the mutant EGFRvIII.
Br J Cancer, 93: 915-923, 2005
110.Poulsen TT, Pedersen N, Poulsen HS: Replacement and suicide gene therapy for targeted treatment of lung cancer.
Clin Lung Cancer, 6: 227-236, 2005
111.Pedersen N, Hansen SE, Heydenreich AV, Kristensen HG. and Poulsen HS: Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands.
Eur J Pharm Biopharm, 62:155-162, 2006
112.Pedersen N, Pedersen MW, Lan MS, Breslin MB, Poulsen HS: The insulinoma-associated 1:a novel promoter for targeted cancer gene therapy for small cell lung cancer.
Cancer Gene Ther, 13: 375-384, 2006.
113.Vestergaard J, Pedersen MW, Pedersen N, Ensinger C, Tümer Z, Tommerup N, Poulsen HS, Larsen LA: Hedgehog signaling in small-cell lung cancer: frequent in vivo but a rare event in vitro.
Lung Cancer, 52:281-290, 2006.
114.Andersen PB, Blinkenberg M, Lassen U, Kosteljanetz M, Wagner A, Poulsen HS, Sørensen PS, Paulson OB: A prospective PET study of patients with glioblastoma multiforme.
Acta Neurol Scand, 113(6): 412-8, 2006.
115.Pedersen MW, Poulsen HS: Mutationer i EGF receptoren: struktur og tumorbiologisk relevans. Ugeskr Læger, 168:2 354-2361, 2006
116.Poulsen HS: Gliomer hos voksne: Primær ikke kirurgisk behandling.
Ugeskr Læger, 168: 4082-5, 2006
117.Spindler K-LG, Olsen DA, Nielsen JN, Brandslund I, Poulsen HS, Villingshøj M, Jakobsen A: Lack of the Type III Epidermal Growth Factor Receptor Mutation in Colorectal Cancer.
Anticancer Res, 26 (6C): 4889-93, 2006.
118.Pedersen N, Poulsen TT, Poulsen HS: CreloxP recombination vectors for promoter studies.
Electron J Biotechol, 10:315-321, 2007
119.Larsen AB, Pedersen MW, Stockhausen M, Grandal MV, van Deurs B, Poulsen HS: Activation of the EGFR target gene EphA2 inhibits EGF-induced cancer cell motility.
Molecular Cancer Research, 5(3): 283-293, 2007.
120.Grandal MV, Zandi R, Pedersen MW, Willumsen BM, van Deurs B, Poulsen HS: EGFRvIII escapes downregulation due to impaired internalization and sorting to lysosomes.
Carcinogenesis, 28(7): 1408-17, 2007
121.Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS: Mechanisms for oncogenic activation of the epidermal growth factor receptor.
Cellular Signalling, 19 (10) 2013-23, 2007
122.Andersen P, Pedersen MW, Woetmann A, Stockhausen MT, Ødum N, Poulsen HS: EGFR induces expression of IRF-1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells.
Int. J. Cancer, Jan 15; 122(2): 342-9, 2008
123.Poulsen TT, Pedersen N, Poulsen HS: A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells.
Cancer Gene Therapy 15: 563-575, 2008
124.Hansen CL, Hansen PR, Pedersen N, Poulsen HS, Gillings N, Kjær A: Identification of amino acid residues in PEPHC1 important for binding to the tumor-specific receptor EGFRvlll.
Chem Biol Drug Des. 72(4): 273-82, 2008.
125.Poulsen TT, Naizhen X, Poulsen HS, Linnoila IR: Acute damage by naphthalene triggers expression of the neuroendocrine marker PGP9.5 in airway epithelial cells.
Toxicol Lett 181: 67-74, 2008.
126.Poulsen HS, Grunnet K, Sørensen M, Olsen P, Hasselbalch B, Kosteljanetz M, Lassen U: Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.
Acta Oncologica. 48(1): 52-8, 2009.
127.Andersen P, Villingshøj M, Poulsen HS, Stockhausen MT: Improved response by co-targeting EGFR/EGFRvIII and Src family kinases in human cancer cells.
Cancer Invest 27 (2): 178-83, 2009
128.Denholt CL, Hansen PR, Pedersen N, Poulsen HS, Gillings N, Kjær A: Identification of novel receptor binding ligands for EFGRvIII using a mixture-based synthetic combinatorial library.
Biopolymers. 91(3): 201-206, 2009.
129.Christensen CL, Zandi R, Gjetting T, Cramer F, Poulsen HS: Specifically targeted gene therapy for small cell lung cancer.
Expert Review of Anticancer therapy. 9(4): 437-52, 2009.
130.Stockhausen MT, Kristoffersen K, Poulsen HS: The Functional role of Notch signaling in human gliomas.
Neuro Oncol. Feb; 12(2): 199-211, 2010.
131.Sørensen M, Gaziel TB, Hasselbalch B, Poulsen HS, Lassen U: Severe skin lesions in patients with glioblastoma multiforme treated with a combination of cetuximab, bevacizumab and irinotecan.
European Journal of Clinical & Medical Oncology 1(2): 1-3, 2009.
132.Larsen AB, Stockhausen M, and Poulsen HS: Cell adhesion and EGFR activation regulate EphA2 expression in cancer.
Cellular Signalling 22:636-644, 2010.
133.Kosteljanetz M, Poulsen HS: Kemoterapi imprægnerede wafers i behandlingen af maligne gliomer i hjernen. En gennemgang af et Cochrane Review.
Ugeskrift for Læger, Jan 18; 172(3): 214-217, 2010.
134.Christensen CL, Gjetting T, Poulsen TT, Cramer F, Roth JA, Poulsen HS: Targeted cytosine deaminase-uracil phosphoribosyl transferase induces SCLC specific cytotoxicity and tumor growth delay.
Clin Cancer Res; April 15; 16(8):2308-19, 2010.
135.Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M, Broholm H, Stockhausen MT, Poulsen HS: Cetuximab, Bevacizumab and Irinotecan for Patients with Primary Glioblastoma and Progression after Radiation Therapy and Temozolomide: A Phase II trial.
Neuro Oncol. May; 12(5): 508-16, 2010.
136.Hasselbalch B, Lassen U, Poulsen HS, Stockhausen MT: Cetuximab is insufficient in inhibiting cell growth due to persistent EGFR downstream signalling.
Cancer Investigation, May 26. 2010.
137.Gjetting T, Arildsen NS, Christensen CL, Poulsen TT, Roth JA, Handlos VN, Poulsen HS: In vitro and in vivo effects of polyethylene glycol (PEG)-modified lipid in DOTAP/cholesterol-mediated gene transfection.
Int. J. Nanomedicine.: Aug.9; 5:371-83, 2010.
138.Bartkova J, Hamerlik P, Stockhausen MT, Ehrmann J, Laursen H, Katita O, Kolar Z, Poulsen HS, Broholm H, Lukas J, Bartek J: Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signaling in human gliomas.
Oncogene.: Sep 9;29(36):5095-102, 2010.
139.Hasselbalch B, Eriksen JG, Broholm H, Christensen IJ, Grunnet K, Horsman MR, Poulsen HS, Stockhausen MT, Lassen U: Prospective evaluation of angiogenic, hypoxic and EGFR related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan.
APMIS, Aug; 118(8): 585-94, 2010.
140.Olszewski U, Poulsen TT, Ulsberger E, Poulsen HS, Geissler K, Hamilton G: Invitro cytotoxity of combinations of dichloroacetate with anticancer platinum compounds.
Clinical Pharmacology: Advances and Applications: 2 1-7, 2010.
141.Madsen K, Poulsen HS: Needs for support in everyday life for next of kin to brain tumor patients: a systematic literature review.
European Journal of Cancer Care. Jan;20(1):33-43, 2011
142.Jakobsen JN, Hasselbalch B, Stockhausen MT, Lassen U, Poulsen HS: Irinotecan and bevacizumab treatment of recurrence of Glioblastoma Multiforme.
Expert Opinion On Pharmacotherapy: Apr; 12(5): 825-33, 2011.
143.Denholt C, Binderup T, Stockhausen MT, Poulsen HS, Spang-Thomsen, Hansen PR, Gillings N, Kjær A: Evaluation of 4-[18F]fluorobenzoyl-FALGEA-NH2 as a Positron Emission Tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer.
Nuclear Medicine and Biology. May; 38(4): 509-15, 2011.
144.Zandi R, Selivanova G, Christensen CL, Gerds TA, Willumsen BM, Poulsen HS:PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in Small Cell Lung Cancer expressing mutant p53.
Clin Cancer Research, May 1; 17(9): 2830-41, 2011
145.Stockhausen MT, Broholm H, Villingshøj M, Kirchhoff M, Gerdes T, Kristoffersen K, Kosteljanetz M, Spang-Thomsen M, and Poulsen HS: Maintenance of EGFR and EGFRvIII expression in an in vivo and in vitro model of human glioblastoma multiforme.
Experimental Cell Research: Jul 1; 317(11): 1513-26, 2011.
146.Gjetting T, Andresen TL, Christensen CL, Poulsen TT, Cramer F, Poulsen HS : A simple protocol for preparation of a liposomal vesicle with encapsulated plasmid DNA that mediate high accumulation and reporter gene activity in tumor tissue. Results in Pharma Sciences 1: 49-56, 2011.
147.Henriksson R, Asklund T, Poulsen HS: Impact of therapy on quality of life, neurocognitive function and their correlates in Glioblastoma Multiforme. J. Neurooncol. : Sep; 104(3): 639-46, 2011.
148.Zandi R, Xu K, Poulsen HS, Roth JA and Ji L: The effect of adenovirus-mediated gene expression of FHIT in small cell lung cancer cells. Cancer Invest. 29(10):683–691, 2011
149.Zandi R, Xu K, Poulsen HS, Roth JA and Ji L: Overexpression of the novel tumor suppressor gene FUS1 suppresses the growth of small cell Lung cancer cells. Clinical and Experimental Pathology. J Clinic Experiment Pathol S5, 12/2011
150.Poulsen HS, Von der Maase H.: MiRNA ved glioblastomer - potentiale og begrænsninger. Ugeskr. Læger, Marts 5; 174(10): 628, 2012
151.Nedergaard MK, Hedegaard CJ, Poulsen HS: Targeting the Epidermal growth factor receptor in solid tumor malignancies. BioDrugs: Apr 1; 26(2):83-99. 2012
152.Stockhausen MT, Kristoffersen K, Poulsen HS: Notch signaling and brain tumors.
Adv Exp Med Biol.727:289-304, 2012
153.Møller S, Grunnet K, Hansen S, Schultz H, Holmberg M, Sorensen M, Poulsen HS, Lassen U: A phase II trial with bevacizumab and irinotecanfor patients with primary brain tumors andprogression after standard therapy. Acta Oncol. Jul;51(6):797-804, 2012.
Michaelsen SR, Christensen CL, Sehested M, Cramer F, Poulsen TT, Patterson AV, Poulsen HS: Single agent- and combination treatment with two targeted gene therapy systems is effective in chemo-resistant small cell lung cancer (SCLC) cells. J Gene Med. Jul;14(7):445-58, 2012
155.Cramer F, Christensen CL, Poulsen TT, Badding MA, Dean DA, Poulsen HS: Insertion of a Nuclear Factor Kappa B DNA Nuclear Targeting Sequence potentiatessuicide gene therapy efficacy in lung cancer cell lines.
Cancer Gene Therapy Oct;19(10):675-83. 2012
156.Bondgaard ALRØ, Poulsen TT, Poulsen HS, Skov BG: Different Expression of EZH2, BMI1 and Ki67 in Low and High Grade Neuroendocrine Tumors of the Lung. Cancer Biomark. 2012;11(2-3):123-8.
Muhic A, Poulsen HS, Sorensen M, Grunnet K, Lassen U: Phase II Open-label Study of Nintedanib in Patients with Recurrent Glioblastoma Multiforme. J Neurooncol. 2013 Jan;111(2):205-12.
158.Kristoffersen K, Villingshøj M, Stockhausen MT, Poulsen HS: Level of Notch activation determines the effect on growth and stem cell-like features in glioblastoma multiforme neurosphere cultures. Cancer Biol Ther. 2013 Jul 1;14(7):625-37.
159.Lassen U, Sørensen M, Gaziel, TB, Hasselbalch B, Poulsen HS: Phase II study of bevacizumab and Temsirolimus combination therapy for recurrent glioblastoma multiforme. Anticancer Research, 2013 Apr;33(4):1657-60.
160.Michaelsen SR, Christensen IJ, Grunnet K, Stockhausen MT, Broholm H, Kostaljanetz M, Poulsen HS: Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme in a cohort of consecutive non-selected patients from a single institution. BMC Cancer. 2013 Sep 3;13(1):402
161.Hofland KF, Hansen S, Sorensen M, Schultz HP, Muhic A, Engelholm S, Grunnet K, Ask A,
Kristiansen C, Thomsen C, Poulsen HS, Lassen U: Neoadjuvant Bevacizumab and Irinotecan versus Bevacizumab and Temozolomide followed by Concomitant Chemoradiotherapy in Newly Diagnosed Glioblastoma Multiforme: A Randomized Phase II Study. Acta Oncol. 2014 Jan 23
162.Stockhausen MT, Kristoffersen K, Olsen MLS, Poulsen HS: Differentiation of human glioblastoma multiforme stem-like cells leads to down regulation of EGFR and EGFRvIII expression and decreased tumorigenic and stem cell potential. Cancer Biol Ther. 2014 Feb 1;15(2):216-24.
163.Kristoffersen K, Nedergaard MK, Villingshøj M, Borup R, Broholm H, Kjær A, Poulsen HS,
Stockhausen MT: Inhibition of Notch signaling alters the phenotype of orthotopic tumors formed from glioblastoma multiforme neurosphere cells but does not hamper intracranial tumor growth regardless of endogene Notch pathway signature. Cancer Biol Ther. 2014 Apr 22;15(7).
164.Poulsen HS, Urup T, Michaelsen SR, Staberg M, Villingshøj M, Lassen U: The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients.Cancer Manag Res.2014:6 373–387
165.Nedergaard M, Kristoffersen K, Michaelsen SR, Poulsen HS, Stockhausen MS, Lasse U, Kjaer A: The use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenografts. PLoS One. 2014; 9(6): e100009.  
166.Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, Chipumuro E, Herter-Sprie GS, Akbay EA,Altabef A, Zhang J, Shimamura T, Capelletti M, Reibel JB, Cavanaugh JD, Gao P, Liu Y, Michaelsen SR, Poulsen HS, Aref AR, Barbie DA,. Bradner JE, George RE, Gray NS, Young RA, Kwok-Kin Wong KK: Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor:Cancer Cell; Volume 26, Issue 6, 8 December 2014, Pages 909–922
Lassen U, Mau-Sørensen M, Poulsen HS: Orphan drugs in development for glioblastoma multiforme: a review. Orphan Drugs: Research and Reviews, nov.2014, 4:83-91
168.Nedergaard MK, Michaelsen SR, Urup T, Broholm H, El Ali H, Poulsen HS, Stockhausen MT, Kjaer A and Lassen U: 18F-FET MicroPET and MicroMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma:PLoS One. 2015 Feb 13:10(2): e0115315.
169.Møller S, Lundemann M, Law I, Poulsen HS, Larsson HBW, Engelholm SA:
Early changes in perfusion of glioblastoma during radio- and chemotherapy evaluated by T1-dynamic contrast enhanced MRI. Acta Oncologica. 2015 Jul 23:1-8. Epub ahead of print
170.Henriksen OM, Larsen VA, Muhic A, Hansen AE, Larsson HBW, Poulsen HS, Law I: Simultaneous evaluation of brain tumor metabolism, structure and blood volume using [18F]-fluoro-ethyl-tyrosine (FET) PET/MRI: feasibility, agreement and initial experiences. European Journal of Nuclear Medicine and Molecular Imaging, 2015 Sep 12. Epub ahead of print
Persson M, Nedergaard MK, Brandt-Larsen M, Skovgaard D, Jørgensen JT,,Michaelsen SR, Madsen SR, Lassen U, Poulsen HS, Kjaer A: uPAR is a promising new imaging biomarker in Glioblastoma.J Nucl Med. 2016 Feb;57(2):272-8.
172.Urup T, Dahlrot RH, Grunnet K, Christensen IJ, Michaelsen SR, Toft A, Larsen VA, Broholm H, Kosteljanetz M, Hansen S, Poulsen HS, Lassen U: Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecants treated with bevacizumab and irinotecan.  Acta Oncol. 2016, Apr;55(4):418-22.
173.Kristensen LS, Michelsen SR, Dyrbye H, Aslan D, Grunnet K, Christensen IJ, Poulsen HS, Grønbæk K, Broholm H: Assessment of quantitative and allelic MGMT methylation patterns as a prognostic marker in glioblastoma. J Neuropathol Exp Neurol. 2016 Feb 16
174.Nedergaard MK, Michaelsen SR, Perryman L, Erler, Poulsen HS, Lassen U, Stockhausen MT and Kjaer A: Comparison of 18F-FET and 18F-FLT MicroPET for the assessment of anti-VEGF efficacy in an orthotopic model of glioblastoma. Nucl Med Biol. 2016 Mar;43(3):198-205.
175.Campos B, Olsen LR, Urup T, Poulsen HS. A Comprehensive Profile of Recurrent Glio-blastoma. Oncogene. 2016 Apr 4. doi: 10. PMID: 27041580.
176.Johansen MD, Rochat P, Law I, Scheie D, Poulsen HS, Muhic A: Presentation of two cases with early extracranial metastases from glioblastoma and review of literature. Case Reports in Oncological Medicine, vol. 2016, Article ID 8190950
177.Staberg M, Michaelsen SR, Olsen LS, Nedergaard MK, Villingshøj M, Hamerlik P, Poulsen HS: Combined EGFR- and Notch inhibition display additive inhibitory effect on Glioblastoma cell viability and Glioblastoma-induced endothelial cell sprouting in vitro. Cancer Cell International.Cancer Cell Int.2016 Apr 26; 16:34. doi: 10.1186. PMID: 27118928
178.Poulsen SH, Urup T, Grunnet K, Christensen IJ, Larsen VA, Rosenschöld PM, Poulsen HS, Law I:
The prognostic value of radiotherapy planning O-(2-18F-fluoroethyl)-L-tyrosine PET in newly
diagnosed glioblastoma. Eur J Nucl Med Mol Imaging. 2016 Aug 23, PMID: 27554774
179.Urup T, Michaelsen SR, Rønn Olsen LR,Toft A, Christensen IJ, Grunnet K, Winther O, Broholm H, Kosteljanetz M, Issazadeh-Navikas S, Poulsen HS, Lassen U: Angiotensinogen and HLA Class II Predict Bevacizumab Response in Recurrent Glioblastoma Patients. Molecular Oncology.Mol Oncol. 2016 Oct;10(8):1160-8. doi: 10.1016 PMID: 27262894
180.Møller S, Law I, Rosenschold PM, Costa J, Poulsen HS, Engelholm SA: Prognostic value of 18F-FET PET imaging in reirradiation of high-grade glioma: Results of a prospective trial. Radiotherapy and Oncology, 2016 Oct;121(1) 132-137.Doi 10.1016, PMID: 27622554
181.Staberg M, Michaelsen SR, Rasmussen RD, Villingshøj M, Poulsen HS, Hamerlik P: Inhibition of histone deacetylases sensitizes glioblastoma cells to Lomustine. Cell Oncol (Dordr). 2016 Oct 20. PMID: 27766591
182.Lundemann M, Costa J, Law I, Engelholm SA, Muhic A, Poulsen HS, Rosenschold PM: Patterns of failure for patients with glioblastoma following O-(2-[18F]fluoroethyl)-L-tyrosine PET- and MRI-guided radiation therapy. Radiother Oncol. 2017 Jan 19. pii: S0167-8140(17)30007-5. Doi 10.1016 PMID: 28110959
183 Urup T, Staunstrup LM, Michaelsen SR, Vitting-Seerup K, Bennedbæk M, Toft A, Olsen LR, Jønson L, Issazadeh-Navikas S, Broholm H, Hamerlik P, Poulsen HS, Lassen U. Transcriptional changes  induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients. BMC Cancer. 2017 Apr 18;17(1):278. doi: 10.1186/s12885-017-3251-3. PMID: 28420326
184Dahlrot RH, Dowsett J, Fosmark S, Malmström A, Henriksson R, Boldt H, de Stricker K, Sørensen MD, Poulsen HS, Lysiak M, Söderkvist P, Rosell J, Hansen S, Kristensen BW: Prognostic value of  MGMT protein expression in glioblastoma excluding non-tumour cells from the analysis. Neuropathol Appl Neurobiol. 2017 Jun 2. doi: 10.1111 PMID: 28574607
185.Nørøxe DS, Poulsen HS, Lassen U: Hallmarks of glioblastoma - a systematic review. Esmoopen. In press.
186.Malmström A, Poulsen HS, Grønberg BH, Stragliotto G, Hansen S, Asklund T, Holmlund B, Łysiak M, Dowsett J, Kristensen BW, Söderkvist P, Rosell, Henriksson R:Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial. Acta Oncology 2017 Jul 4:1-10. doi: 10.1080/0284186X.2017.1332780. PMID:28675067
187.Møller S, Munck Af Rosenschöld P, Costa J, Law I, Poulsen HS, Engelholm SA, Engelholm S: Toxicity and efficacy of re-irradiation of high-grade glioma in a phase I dose- and volume escalation trial. Radiother Oncol. 2017 Oct 17. pii: S0167-8140(17)32625-7. doi: 10.1016/j.radonc.2017.09.039. PMID: 29054380
188.Michaelsen SR, Urup T, Olsen LR, Broholm H, Lassen U, Poulsen HS: Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival. J Neurooncol. 2018 May;137(3):533-542. doi: 10.1007/s11060-017-2739-7. Epub 2018 Jan 5
189.Michaelsen SR, Aslan D, Urup T, Poulsen HS, Grønbæk K, Broholm H, Kristensen LS: DNA Methylation Levels of the ELMO Gene Promoter CpG Islands in Human Glioblastomas Int J Mol Sci. 2018 Feb 28;19(3). pii: E679. doi: 10.3390/ijms19030679.PMID: 29495584
 190.Toft A, Urup T, Christensen IJ, Michaelsen SR, Lukram B, Grunnet K, Kosteljanetz M, Larsen AVA,
Lassen U, Broholm H, Poulsen HS: Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan. Cancer Invest. 2018 Feb 7;36(2):165-174. doi: 10.1080/07357907.2018.1430818. Epub 2018 Feb 2. Reveiw PMID: 29393706
 191.Staberg M, Rasmussen RD, Michaelsen SR, Pedersen H, Jensen KE, Villingshøj M, Skjoth Rasmussen J, Brennum J, Vitting-Seerup K, Poulsen HS, Hamerlik P: Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B. Mol Oncol. 2018 Mar;12(3):406-420. doi: 10.1002/1878-0261.12174. Epub 2018 Feb 12. PMID: 29360266
192.Jakobsen JN, Urup T, Grunnet K, Toft A, Johansen MD, Poulsen SH, Christensen IJ, Muhic A, Poulsen HS: Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.J Neurooncol. 2018 Apr;137(2):439-446. doi: 10.1007/s11060-017-2736-x. Epub 2018 Jan 12. PMID: 29330749
193.Michaelsen SR, Staberg M, Pedersen H, Jensen KE, Majewski W, Broholm H, Nedergaard MK, Meulengracht C, Urup T, Villingshøj M, Lukacova S, Skjøth-Rasmussen J, Brennum J, Kjær A, Lassen U, Stockhausen MT, Poulsen HS, Hamerlik: VEGF-C Sustainns VEGFR2 Activation under Bevacizumab therapy and promotes Glioblastoma Maintenance. Neuro Oncol. 2018 Jun 25. doi:10.1093/neuonc/noy103. [Epub ahead of print] PMID: 29939339
194.Galldiks N, Dunkl V, Ceccon G, Tscherpel C, Stoffels G, Law I, Henriksen OM, Muhic A, Poulsen HS, Steger J, Bauer EK, Lohmann P, Schmidt M, Shah NJ, Fink GR, Langen KJ: Early treatment Response evaluation using FET PET compared to MRI in glioblastoma patients at first progression Treated with bevacizumab plus Lomustine. Eur J Nucl Med Mol Imaging. 2018 Jul 7. doi: 10.1007/s00259-018-4082-4. [Epub ahead of print] PMID:29998284
195.Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg HS, Straten PT, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A: Identification of tumor antigens among the HLA peptidomes of Glioblastoma tumors and plasma. Mol Cell Proteomics. 2018 Aug 2. pii: mcp.RA118.000792. doi: 10.1074/mcp.RA118.000792. [Epub ahead of print] PMID: 3007257
196.Lundemann M, Rosenschöld PM, Muhic A, Larsen VA, Poulsen HS, Engelholm SA , Andersen FL, Kjær A, Larsson HBW , Law I, Hansen AE: Feasibility of multi-parametric PET and .MRI for prediction of tumour recurrence in patients with glioblastoma. Eur J Nucl Med and Mol Imagingn2018 Oct 2. doi: 10.1007/s00259-018-4180-3. [Epub ahead of print] PMID: 30276440.
197.Munck Af Rosenschold P, Law I, Engelholm S, Engelholm SA, Muhic A, Lundemann MJ, Roed H, Grunnet K, Poulsen HS. Influence of volumetric modulated arc therapy and FET-PET scanning on treatment outcomes for glioblastoma patients. Radiother Oncol. 2018 Nov 13. pii: S0167-8140(18)33508-4. doi: 10.1016/j.radonc.2018.10.003. [Epub ahead of print] PMID: 30446316
198.Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.: Actively personalized vaccination trial for newly diagnosed glioblastoma.
Nature. 2018 Dec 19. doi: 10.1038/s41586-018-0810-y. [Epub ahead of print] PMID: 30568303
199. Johansen MD, Urup T, Holst CB, Christensen IJ, Grunnet K, Lassen U, Friis S, Poulsen HS:
Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors. Cancer Investigation. Pages 512-519, Published online: 07 Jan 2019


Articles submitted:
1.Møller S, Rosenschöld PM, Parsons M, Poulsen HS, Engelholm SA: Cognitive function before and after re-irradiation of high-grade glioma: feasibility and initial results of a prospective trial. Submitted
2.Perryman L, Høye AM,Cox TR, Strøbech J, Leonte L, Singh LB, Popov S, Poulsen HS, Jones C, Erler JT: Laminin modification attracts glioblastoma cells to invade the perivascular niche. Submitted.
3.Piil K, Christensen IJ, Grunnet K, Poulsen HS: Health-related quality of life in long-term survivors of glioblastoma - A mixed-methods study. Submitted.
4.Bashir A, Jacobsen SM, Henriksen OM, Broholm, Urup T, Grunnet K, Larsen VA, Møller S, Skjøth-Rasmussen J, Poulsen HS, Law I:Recurrent glioblastoma versus late posttreatment changes: Diagnostic accuracy of O-
(2-18Ffluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET). Submitted.
5.Nørøxe DS, Østrup O, Yde CW, Ahlborn LB, Nielsen FC, Michaelsen SR, Larsen VA, Skjøth-Rasmussen J, Brennum J, Hamerlik P, Poulsen HS, Lassen U: Cell-free DNA in newly diagnosed patients with glioblastoma – a clinical prospective feasibility study. Submitted

Articles without peer review:
1.Poulsen HS, Ozzello L, King WJ, Greene GL: Immunocytochemistry of oestrogen receptors in human breast cancer. Reviews Endocrine-Rel Cancer 19: 21-26, 1986.
2.Brünner N, Spang-Thomsen M, Poulsen HS, Vindeløv L, Engelholm SA:  Effect of tamoxifen on growth and cell kinetics of two human breast carcinomas grown in nude mice. Reviews Endocrine-Rel Cancer 19: 125-130, 1986.
3.Ørntoft T, Bendtsen L, Poulsen HS, Petersen SE, Wolf H, Pedersen S, Bolund L: Dual parameter flow cytometric measurement of DNA-content and lectin binding in human bladder tumors
In: Lectins, vol. V. TC Bøg-Hansen, E. van Driessche (eds). Berlin - New York. Walter de Gruyter & Co. pp. 545-550, 1986
4.Brünner N, Spang-Thomsen M, Poulsen HS, Vindeløv L, Engelholm SA: Characterization of the T60 human breast carcinoma grown in nude mice: special reference to endocrine therapy studies.
In: Immune-deficient Animals in Biochemical Research. Rygaard J, Spang-Thomsen M, Brünner N Græm N. Basel: Karger Publishing, pp. 234-241, 1987.
5.Poulsen HS, Rytter L, Brünner N, Ørntoft T, Andersen J, Spang-Thomsen M: Steroid receptor profile in human breast cancer grown in nude mice.
In: Immune-deficient Animals in Biochemical Research. J. Rygaard, M. Spang-Thomsen, N. Brünner, N. Græm (eds). Basel, Karger Publishing, pp. 255-259, 1987.
6.Brünner N, Poulsen HS, Clarke R, Spang-Thomsen M: Effect of oophorectomy on estrogen and progesterone receptor concentrations in an ovarian-dependent and ovarian independent human breast cancer grown in nude mice.
In: Wu B-q, Zheng J (eds): Immune-deficient Animals in Experimental Medicine. 6 th. Int. Workshop on Immune-deficient animals, Karger, Basel, pp: 196-201, 1989.
7.Damstrup L, Andersen J, Kufe DW, Hayes DF, Poulsen HS: Estrogen-regulated proteins in human breast cancer: Clinical value in advanced breast cancer and correlation with estrogen receptor.
In: Recent advances in cellular and molecular biology, edited by Wegman,R.J. and Wegman,M.A., Leuven, Belgium: Peeters Press, p. 243-251, 1992.
8.Krarup M, Poulsen HS, Spang-Thomsen M: Expression of cell cycle regulating mRNA in small cell lung cancer xenografts.
Folia Microbiologica 43: 501 - 503, 1998.
9.Poulsen HS, Ulrichsen H. Kommentar: Når læger laver medicin.
Ugeskrift Læger 40: 5545 – 5546, 2001.

1.Poulsen HS. In vitro observations in relation to response, Chp.7.
In: Endocrine Management of Cancer 1: Biological bases. B. Stoll (ed). Basel: Karger Publishing 1988, pp. 72-83.
2.Olsen I, Poulsen HS, Kosteljanetz M. Værd at vide om hjernesvulster.
Finsencenter, Rigshospitalet 1996, 1- 36.
3.Geisling PQ, Poulsen HS, Kosteljanetz M. Hjernesvulster.
Kræftens Bekæmpelse, 1996, 1- 36.
4.Hougaard S, Nørgaard P, Poulsen HS. TGFb and lung cancer.
In: J.R. Benson: TGF- beta and Cancer. Landes Bioscience Publishers 1997.
5.Frederiksen KS, Petri A, Abrahamsen N, Poulsen HS. Gene therapy of Lung Cancer.
In: F. Hirch: Lung Cancer, 1999.
6.Poulsen TT, Pappot H, Poulsen HS. Molecular Biology in Lung Cancer. In: Hansen HH, IASLC Textbook on Lung Cancer, 2nd edition, Informa Healthcare, 2008.
7.Hasselbalch B, Lassen U, Poulsen HS. Patients with Recurrent High-Grade Glioma. Therapy with Combination of Bevacizumab and Irinotecan. In: M.A. Hayat, Tumors of the central nervous system. Volume 2. Springer 2011, pp 289-301.
8.Stockhausen MT, Kristoffersen K, Poulsen HS. Notch Signaling and Brain Tumors. In: Reichrath J and Reichrath S. Notch Signaling in Embryology and Cancer. Landes Bioscience, and Springer, 2011.
9.Nilbert M, Poulsen HS.CNS tumörer. In Nilbeert M: Handbok i klinisk onkologi. Studenterlitteratur, 2013, pp 183-185
10.Johansen MD, Poulsen HS: Diagnostik og behandling af glioblastom. BestPractice Onkologi; Submitted
1.Co- inventor of: Targeted gene therapy in small cell lung cancer. 2000-03-17
(Agent: Ploughmann, Vingtoft & Partners).
2.Co- inventor af: Oncology Drug Innovation. Receptorer og promotorer til genterapi. 2001-06-25
Patent PA 2001 00992 og 2002 (Agent: Høiberg Aps) Publication date 3. January 2003, Patent number WO03000928.
3.Co-inventor af: Insulinoma Associated-1 promoter-specific therapy of neuroendocrine tumors. 2005
(Agent: Taylor, Porter, Brooks & Phillips L.L.P).
International reviews:
1.Bunn P, Carbone D, Grim J, Harris C, Havemann K, Mabry M, Roth J, Saijo N,
Poulsen HS, Stahel R, Takahashi T, Twentyman P.
Fifth I.A.S.L.C. Lung Tumor Biology Workshop, August 13 - 17, 1996, Ermatingen, Switzerland. Commentary.
Ann Oncology 8: 27 - 36, 1997.
2.Bunn P, Carbone D, Grim J, Harris C, Havemann K, Mabry M, Roth J, Saijo N,
Poulsen HS, Stahel R, Takahashi T, Twentyman P.
Fifth I.A.S.L.C. Lung Tumor Biology Workshop, August 13 - 17, 1996, Ermatingen, Switzerland. Commentary.
Lung Cancer 16: 239 - 257, 1997.




The Finsencenter, Section 6321, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark